Core Insights - Sana Biotechnology, Inc. focuses on developing ex vivo hypoimmune therapy and in vivo fusogen-based delivery systems to treat cancer and autoimmune diseases [1] Company Overview - The company is engaged in innovative biotechnological solutions aimed at addressing significant medical challenges in oncology and autoimmune disorders [1] Technology and Innovation - Sana's ex vivo platform is designed to enhance therapeutic efficacy by utilizing hypoimmune strategies, which may improve patient outcomes in complex diseases [1]